Decreased Expression of CPEB3 Predicts a Poor Prognosis in Patients with Melanoma: A Study Based on TCGA Data

Table 2

Logistic regression analysis of CPEB3 expression associated with clinical pathological characteristics.

Characteristics	Total ()	Odds ratio in CPEB3 expression	value
New event type (metastasis vs. recurrence)	173	0.51 (0.26-0.98)	0.045
T stage (T0-2 vs. T3-4)	384	0.56 (0.37-0.85)	0.006
N stage (N0 vs. N1-3)	411	0.96 (0.65-1.42)	0.843
M stage (M0 vs. M1)	440	1.04 (0.45-2.39)	0.927
Clinical stage (stages 0-II vs. stages III-IV)	416	0.99 (0.68-1.46)	0.972
Melanoma Clark level (I-III vs. IV-V)	319	0.54 (0.33-0.87)	0.012
Tumor status (tumor free vs. with tumor)	460	0.84 (0.58-1.21)	0.35
Tumor tissue site (extremities vs. trunk)	366	0.73 (0.48-1.10)	0.134
Melanoma ulceration (no vs. yes)	311	0.61 (0.39-0.95)	0.029